Alzinova: CRO selected for phase II study and new CSF data - Redeye

Redeye comments on Alzinova’s recent announcements of a strategic collaboration with Worldwide Clinical Trials and promising new CSF data. We see the selection of Worldwide as CRO for the upcoming phase II trial as a positive step, given its strong track record in managing large-scale Alzheimer’s studies. In addition, we are also encouraged by the new CSF findings supporting ALZ-101’s ability to elicit an immune response that reaches the brain.

Länk till analysen i sin helhet: https://www.redeye.se/research/1115895/alzinova-cro-selected-for-phase-ii-study-and-new-csf-data?utm_source=finwire&utm_medium=RSS